Kaohsiung Journal of Medical Sciences (Feb 2024)

Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs

  • Tyng‐Yuan Jang,
  • Po‐Cheng Liang,
  • Dae Won Jun,
  • Jang Han Jung,
  • Hidenori Toyoda,
  • Chih‐Wen Wang,
  • Man‐Fung Yuen,
  • Ka Shing Cheung,
  • Satoshi Yasuda,
  • Sung Eun Kim,
  • Eileen L. Yoon,
  • Jihyun An,
  • Masaru Enomoto,
  • Ritsuzo Kozuka,
  • Makoto Chuma,
  • Akito Nozaki,
  • Toru Ishikawa,
  • Tsunamasa Watanabe,
  • Masanori Atsukawa,
  • Taeang Arai,
  • Korenobu Hayama,
  • Masatoshi Ishigami,
  • Yong Kyun Cho,
  • Eiichi Ogawa,
  • Hyoung Su Kim,
  • Jae‐Jun Shim,
  • Haruki Uojima,
  • Soung Won Jeong,
  • Sang Bong Ahn,
  • Koichi Takaguchi,
  • Tomonori Senoh,
  • Maria Buti,
  • Elena Vargas‐Accarino,
  • Hiroshi Abe,
  • Hirokazu Takahashi,
  • Kaori Inoue,
  • Jee‐Fu Huang,
  • Wan‐Long Chuang,
  • Ming‐Lun Yeh,
  • Chia‐Yen Dai,
  • Chung‐Feng Huang,
  • Mindie H. Nguyen,
  • Ming‐Lung Yu

DOI
https://doi.org/10.1002/kjm2.12771
Journal volume & issue
Vol. 40, no. 2
pp. 188 – 197

Abstract

Read online

Abstract Elevated serum gamma‐glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)‐related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month‐6) after initiating NAs were measured to explore their association with all‐cause, liver‐related, and non‐liver‐related mortality. The annual incidence of all‐cause mortality was 0.9/100 person‐years over a follow‐up period of 17,436.3 person‐years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L, p = 0.002) and Month‐6‐GGT levels (62.1 vs. 38.4 U/L, p 75 percentile of pretreatment GGT levels was observed with respect to the all‐cause mortality (trend p < 0.001). Pretreatment serum GGT levels predicted all‐cause, liver‐related, and non‐liver‐related mortality in patients with CHB treated with NAs.

Keywords